Cardiac resynchronization therapy in patients with minimally symptomatic heart failure

References

• Epstein AE, DiMarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmic Devices). J. Am. Coll. Cardiol.51, e1–e62 (2008).
   PubMedGoogle Scholar
• Dickstein K, Cohen-Solal A, Filippatos G et al.; European Society of Cardiology; Heart Failure Association of the ESC (HFA); European Society of Intensive Care Medicine (ESICM). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail.10, 933–989 (2008).
   PubMed Web of Science ®Google Scholar
• Cazeau S, Leclercq C, Lavergne T et al.; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N. Engl. J. Med.344(12), 873–880 (2001).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fisher WG, Smith AL et al.; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med.346(24), 1845–1853 (2002).
   PubMed Web of Science ®Google Scholar
• Young JB, Abraham WT, Smith AL et al.; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA289(20), 2685–2694 (2003).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med.350(21), 2140–2150 (2004).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352(15), 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Yu CM, Bleeker GB, Fung JW et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation112, 1580–1586 (2005).
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med.352(3), 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation112, e154–e235 (2005).
   PubMed Web of Science ®Google Scholar
• Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. Circulation87(6 Suppl.), VI24–VI31 (1993).
   PubMedGoogle Scholar
• Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J. Am. Coll. Cardiol.46, 2183–2192 (2005).
   PubMed Web of Science ®Google Scholar
• Ghio S, Constantin C, Klersy C et al. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur. Heart J.25(7), 571–578 (2004).
   PubMed Web of Science ®Google Scholar
• Gerdes AM, Kellerman SE, Moore JA et al. Structural remodeling of cardiac myocytes from patients with chronic ischemic heart disease. Circulation86, 426–430 (1992).
   PubMedGoogle Scholar
• Auricchio A, Fantoni C, Regoli F et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation109, 1133–1139 (2004).
   PubMed Web of Science ®Google Scholar
• Blanc JJ, Etienne Y, Gilard M et al. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. Circulation96(10), 3273–3277 (1997).
   PubMed Web of Science ®Google Scholar
• Kass DA, Chen CH, Curry C et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation99(12), 1567–1573 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson GS, Berger RD, Fetics BJ et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation102(25), 3053–3059 (2000).
   PubMed Web of Science ®Google Scholar
• Vanderheyden M, Mullens W, Delrue L et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J. Am. Coll. Cardiol.51, 129–136 (2008).
   PubMed Web of Science ®Google Scholar
• Linde C, Leclercq C, Rex S et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the Multisite Stimulation in Cardiomyopathy (MUSTIC) study. J. Am. Coll. Cardiol.40, 111–118 (2002).
   PubMed Web of Science ®Google Scholar
• Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J. Am. Coll. Cardiol.42(8), 1454–1459 (2003).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Young JB, León AR et al.; Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation110(18), 2864–2868 (2004).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Freemantle N, Daubert JC, Toff WD, Leisch F, Tavazzi L. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart94(3), 278–283 (2008).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS et al.; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med.361(14), 1329–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Linde C, Abraham WT, Gold MR et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J. Am. Coll. Cardiol.52, 1834–1843 (2008).
   PubMed Web of Science ®Google Scholar
• St John Sutton M, Ghio S, Plappert T et al.; Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation120(19), 1858–1865 (2009).
   PubMedGoogle Scholar
• Daubert C, Gold MR, Abraham WT et al.; REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J. Am. Coll. Cardiol.54(20), 1837–1846 (2009).
   PubMed Web of Science ®Google Scholar